Hefei Lifang Pharmaceutical Co., Ltd. announced that its products, doxazosin mesylate extended-release tablets and azilsartan medoxomil potassium tablets, have been selected for the 12th national centralized drug procurement. Doxazosin mesylate extended-release tablets generated sales revenue of 103.4095 million yuan in 2025, accounting for 6.66% of the company's 2025 operating revenue, and 25.3194 million yuan in the first quarter of 2026, accounting for 7.09%. Azilsartan medoxomil potassium tablets were approved for market on May 19, 2026, and have not yet generated sales revenue. The procurement cycle runs from the implementation date of the selection results until December 31, 2029. The company stated that the selection will help increase product market share, but the final agreed procurement volume has not yet been determined.
Hefei Lifeon Pharmaceutical Co LtdDrugs selected for national procurement, likely increasing market share and sales.
